[Congressional Bills 113th Congress]
[From the U.S. Government Publishing Office]
[S. 2007 Introduced in Senate (IS)]
113th CONGRESS
2d Session
S. 2007
To amend the Federal Food, Drug, and Cosmetic Act to provide for
regulating clinical and health software, and for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
February 10, 2014
Mrs. Fischer (for herself, Mr. King, and Mr. Rubio) introduced the
following bill; which was read twice and referred to the Committee on
Health, Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to provide for
regulating clinical and health software, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Preventing Regulatory Overreach To
Enhance Care Technology Act of 2014'' or the ``PROTECT Act of 2014''.
SEC. 2. FINDINGS; SENSE OF CONGRESS.
(a) Findings.--Congress finds as follows:
(1) The mobile health and mobile application economy was
created in the United States and is now being exported
globally, with the market expected to exceed $26,000,000,000 by
2017.
(2) The United States mobile application economy is
responsible for nearly 500,000 new jobs in the United States.
(3) Consumer health information technologies, including
smart phones and tablets, have the potential to transform
health care delivery through reduced systemic costs, improved
patient safety, and better clinical outcomes.
(4) Clinical and health software innovation cycles evolve
and move faster than the existing regulatory approval
processes.
(5) Consumers and innovators need a new risk-based
framework for the oversight of clinical and health software
that improves on the framework of the Food and Drug
Administration.
(6) A working group convened jointly by the Food and Drug
Administration, the Federal Communications Commission, and the
Office of the National Coordinator for Health Information
Technology identified in a report that there are several major
barriers to the effective regulation of health information
technology that cannot be alleviated without changes to
existing law.
(b) Sense of Congress.--It is the sense of Congress that--
(1) the President and Congress must intervene to facilitate
interagency coordination across regulators that focuses agency
efforts on fostering health information technology and mobile
health innovation while better protecting patient safety,
improving health care, and creating jobs in the United States;
(2) the President and the Congress should work together to
develop and enact legislation that establishes a risk-based
regulatory framework for such clinical software and health
software that reduces regulatory burdens, fosters innovation,
and, most importantly, improves patient safety;
(3) The National Institute of Standards and Technology
should be the Federal agency that has oversight over technical
standards used by clinical software; and
(4) The National Institute of Standards and Technology, in
collaboration with the Federal Communications Commission, the
National Patient Safety Foundation, and the Office of the
National Coordinator for Health Information Technology, should
work on next steps, beyond current oversight efforts, regarding
health information technology, such as collaborating with
nongovernmental entities to develop certification processes and
to promote best practice standards.
SEC. 3. CLINICAL SOFTWARE AND HEALTH SOFTWARE.
(a) Definitions.--Section 201 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 321) is amended by adding at the end the
following:
``(ss)(1) The term `clinical software' means clinical decision
support software or other software (including any associated hardware
and process dependencies) intended for human or animal use that--
``(A) captures, analyzes, changes, or presents patient or
population clinical data or information and may recommend
courses of clinical action, but does not directly change the
structure or any function of the body of man or other animals;
and
``(B) is intended to be marketed for use only by a health
care provider in a health care setting.
``(2) The term `health software' means software (including any
associated hardware and process dependencies) that is not clinical
software and--
``(A) that captures, analyzes, changes, or presents patient
or population clinical data or information;
``(B) that supports administrative or operational aspects
of health care and is not used in the direct delivery of
patient care; or
``(C) whose primary purpose is to act as a platform for a
secondary software, to run or act as a mechanism for
connectivity, or to store data.
``(3) The terms `clinical software' and `health software' do not
include software--
``(A) that is intended to interpret patient-specific device
data and directly diagnose a patient or user without the
intervention of a health care provider;
``(B) that conducts analysis of radiological or imaging
data in order to provide patient-specific diagnostic and
treatment advice to a health care provider;
``(C) whose primary purpose is integral to the function of
a drug or device; or
``(D) that is a component of a device.''.
(b) Prohibition.--Subchapter A of chapter V of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended by adding at
the end the following:
``SEC. 524B. CLINICAL SOFTWARE AND HEALTH SOFTWARE.
``Clinical software and health software shall not be subject to
regulation under this Act.''.
SEC. 4. EXCLUSION FROM DEFINITION OF DEVICE.
Section 201(h) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 321(h)) is amended by adding at the end ``The term `device' does
not include clinical software or health software.''.
<all>